Compassionate use, also known as expanded access, is a program that allows patients with serious or life-threatening conditions to obtain experimental treatments that have not yet received full regulatory approval. It provides a potential option for individuals who have exhausted other approved therapies and have no other satisfactory treatment available.
AI-generated content
Compassionate use programs primarily benefit patients suffering from rare or incurable diseases like ALS, childhood genetic disorders, and certain cancers. These patients often have urgent medical needs and limited treatment options, making access to experimental therapies a critical consideration.
AI-generated content
Concerns exist about the affordability and insurance coverage of treatments accessed through compassionate use programs. High drug costs and lack of insurance reimbursement can limit patient access, raising issues of fairness and financial burden for individuals seeking potentially life-saving experimental therapies.
AI-generated content
Regulatory agencies and legislators play key roles in enabling or expanding compassionate use programs by creating policies and laws that govern access to experimental treatments. These bodies can support legislation that clarifies patient eligibility, protects patient rights, and ensures timely availability of experimental drugs for those in urgent need.